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Abstract
Objective—To determine if midpregnancy levels of angiogenic markers were associated with
increased risk of preterm delivery (PTD).
Methods—We studied a subcohort from the Pregnancy Outcomes and Community Health Study
for whom midpregnancy angiogenic markers [(soluble fms-like tyrosine kinase-1 (sFlt-1), soluble
endoglin (sEng), and placental growth factor (PlGF)], and covariate data were available (N =
1301). Angiogenic marker levels were grouped as High/Not High (sFlt-1 & sEng), Low/Not Low
(PlGF) and High/Intermediate/Low (sFlt-1). Associations between levels of angiogenic markers
and PTD/PTD subtype were determined for women who were non-smokers during pregnancy
(N=933).
Results—Low PlGF and High sEng were associated with medically-indicated PTD and PTD <35
weeks, largely due to preeclampsia. Excluding preeclampsia and small-for-gestational-age infants,
Low sFlt-1 was positively associated with medically-indicated PTD.
Conclusions—Among non-smokers midpregnancy levels of angiogenic markers may mark
multiple pathways leading to PTD, only one attributable to preeclampsia.
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Rates of preterm delivery (PTD), delivery at <37 weeks gestational age, have been rising
since 1980[1]. Currently, 1 in 8 US births[1] occurs preterm resulting in substantial
economic, social and long-term health costs[2]. The heterogeneous etiology of PTD
complicates the identification of causal factors and makes prediction difficult[1]. Identifying
the biological pathways involved may improve etiologic studies of PTD[3].
Preeclampsia (PE), characterized by de-novo onset of hypertension and proteinuria after 20
weeks’ gestation, is an important cause of preterm delivery[4]. Altered angiogenic marker
expression is associated with hypertension and proteinuria[5–7]. Increased levels of the
angiogenic markers soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng)
and lower placental growth factor (PlGF) levels may permit detection of PE before symptom
onset[4,6]. Associations between these markers and preeclampsia development appear to be
stronger and more predictive of risk for severe preeclampsia cases that are early-onset or
result in delivery of a small-for-gestational age infant[4]. Altered marker levels may
accompany poor infant growth in the absence of PE, however, the marker pattern involved is
unclear[8,9].
During pregnancy sFlt-1, PlGF and sEng are produced by trophoblasts, although other cell
types may contribute to overall levels[10–12]. Angiogenic marker levels in maternal blood
are dynamic[8] and changing levels of markers may influence aspects of placental
development and angiogenesis[4,10] including spiral artery remodeling and contribute to
maternal pregnancy complications[5,6,13]. While altered marker expression is linked to
placental problems, the time order of events is unclear[4].
Relations between angiogenic markers and PTD are important to characterize. In the US
slightly more than 40% of medically-indicated PTD <37 weeks[14] and >20% occurring
<35 weeks[15] are due to PE. PTD in the absence of PE symptoms is linked to poor
placental development and/or function[16,17]. Little is known about angiogenic marker
patterns in relation to PTD uncomplicated by PE. PE-like angiogenic marker changes have
been reported late in pregnancy among spontaneous preterm labor cases, however similar
changes occur in term pregnancies before labor onset[17]. Two previous reports suggest low
sFlt-1 levels may mark a subset of spontaneous PTD[17,18].
We measured mid-pregnancy levels of sFlt-1, PlGF, and sEng in maternal blood and
assessed their associations with PTD in the Pregnancy Outcomes and Community Health
(POUCH) Study. Our objectives were to: 1) determine if altered marker expression was
associated with increased risk of PTD (primary); and 2) consider the degree to which PE and
small-for-gestational age influenced associations (secondary). Based on prior reports, we
examined two patterns of marker expression: PE-like (increased sFlt-1 and sEng, decreased
PlGF) and Low sFlt-1.
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Between September 1998 and June 2004, the POUCH Study recruited pregnant women from
52 prenatal clinics across 5 Michigan communities at 15–27 weeks’ gestation[3]. Sampling
into the cohort has been described previously[19]. Briefly, participants had maternal serum
α-fetoprotein (MSAFP) screening at 15–22 weeks’ gestation, were ≥15 years old, spoke
English, had singleton pregnancies without known anomalies and did not have pre-
pregnancy diabetes. At enrollment, self-completed questionnaires and in-person interviews
were administered and maternal biologic samples collected. Of 3038 women recruited, 3019
were followed through delivery and constitute the cohort. Study protocols were approved by
institutional review boards at Michigan State University, Michigan Department of
Community Health and delivery hospitals.
Study Sample
To study PTD and at-risk groups of women in greater detail, we established a subcohort in
which we collected additional information (N=1371). The subcohort included all women
delivering preterm or with elevated MSAFP at screening, and a random sample of term
births with normal MSAFP oversampled for African-Americans. The Angiogenic Sample
included 1301 women who belonged to the subcohort, had angiogenic markers measured
and complete information on important covariates (N=1301, Figure 1). The analyses focus
on 933 non-smokers within the Angiogenic Sample. To account for oversampling of PTD
and at-risk groups into the subcohort, weights based on the probabilities of selection into the
cohort and subcohort were applied in all analyses.
Covariates
Race, smoking status and prepregnancy weight were self-reported. Women were grouped as
African-American or non-African-American and as smokers or non-smokers based on
smoking status at the start of pregnancy. Maternal weight was measured at enrollment.
Gestational age (GA) at study enrollment was based on last menstrual period if the estimate
was within 2 weeks of estimates based on <25 week ultrasound. Otherwise, ultrasound dates
were utilized.
Angiogenic Markers
Maternal serum samples were collected at enrollment and stored at −80°C. Batched samples
were analyzed in duplicate using commercially available ELISA kits as described
previously[19].
Outcomes
PTD was any delivery occurring <37 weeks GA. Additionally, PTD was grouped into
subtypes based on: 1) circumstance initiating delivery: premature rupture of membranes
(PPROM), spontaneous preterm labor (sPTL), or medical indications (MI-PTD) or 2) timing
of delivery: term, 35–36, 32–34 and <32 weeks. Based on chart review, PE was defined by
diagnosis of gestational hypertension (diastolic blood pressure ≥90 or systolic blood
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pressure ≥140 on 2 different days) beginning after 20 weeks gestation plus one of the
following as evidence of proteinuria in the absence of genitourinary infection: 1) 2+ protein
on urine dipstick once after 20 weeks gestation, 2) 1+ protein on two occasions after 20
weeks or 3) if proteinuria was present before 20 weeks, increased levels after 20
weeks[20,21]. Women could also have PE superimposed on chronic hypertension beginning
before 20 weeks. SGA was defined as ≤10th centile of weight for gestational age and sex of
infant[22]. Analytic Approach: We began by confirming that the well-established PE-like
pattern of marker expression (increased sFlt-1 and sEng, decreased PlGF) reviewed in [4]
was evident among PE cases in our sample. Since it is unclear whether SGA cases exhibit
the entire PE-like pattern or only particular elements[8,9], we compared adjusted-mean
biomarker levels among all pregnancies complicated by PE (including PE+SGA cases), the
remaining SGA cases and a referent group (no PE/SGA cases). Covariates associated with
angiogenic marker levels in the POUCH study were utilized for adjustment: GA at sample
collection, maternal age, race, smoking status, parity, and maternal weight at blood
sampling, which was highly correlated with self-reported pre-pregnancy weight (r2 = 0.92)
[19].
Early in our analysis we found evidence for different relationships among angiogenic
markers and pregnancy outcome in smokers vs. nonsmokers. Associations between smoking
and angiogenic marker levels[13,23] have been reported but are challenging to interpret in
the context of smoking’s inverse relation to PE and positive association with SGA[24].
Given these complexities, we removed smokers from all analyses and studied women who
were nonsmokers throughout pregnancy (N=933).
The primary analytical objective was to determine if the odds of PTD among non-smokers
were increased when either pattern of marker expression was observed at midpregnancy: 1)
the PE-like pattern associated with PE in this study and others[4,6] or 2) Low sFlt-1
previously associated with increased odds of spontaneous PTD[17,18].
To create groups representing the PE-like pattern, markers were dichotomized using
distributions in term pregnancies among nonsmoking mothers with normal MSAFP: High/
Not-High based on the highest quartile (sFlt-1 & sEng) and Low/Not-Low based on the
lowest quartile (PlGF). To examine low sFlt-1, a 3-level variable was created: High (highest
quartile), Intermediate (middle quartiles) and Low (lowest quartile). Since marker levels
change through pregnancy[8] and sampling occurred between 15–27 weeks’ GA, we
established separate cut-points across three GA windows: 15–<19, 19–<23, and 23–27
weeks.
Using logistic regression, associations between categories of angiogenic marker expression
and odds of PTD were examined. Polytomous regressions were utilized for PTD outcome
categorized according to both clinical circumstance and delivery timing. Models were
adjusted for covariates used to calculate adjusted means. Since associations between
angiogenic markers and PPROM or sPTL did not differ, results are presented for the
composite grouping spontaneous PTD (sPTD).
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The secondary analytical objective was to determine if PE and SGA, previously associated
with altered mid-pregnancy levels of angiogenic markers,[6,8,13] fully account for relations
between angiogenic markers and PTD. After removing PE and SGA cases, all analyses were
repeated.
Analyses were performed in SAS 9.2 (SAS Institute, Cary, NC) using survey procedures,
which incorporate sampling weights to account for study design.
Results
Sample
Weighted percentages describing characteristics of the Angiogenic Sample were not
different from those of the entire POUCH subcohort (Table I). Approximately ¼ of were
African-American, the average age was 26.6 years, 58.9% were multiparous, and 10%
experienced a hypertensive disorder in pregnancy. Preterm deliveries comprised 10.5% of
all deliveries. Women who were nonsmokers during pregnancy were like the entire
Angiogenic Sample, except for being older and less likely to deliver SGA infants.
Angiogenic Marker Levels Among PE and SGA
We first confirmed the well-established pattern of marker expression among all PE cases[4]
(increased sFlt-1 and sEng, decreased PlGF) in POUCH study data. Among nonsmokers,
unadjusted and adjusted levels of sFlt-1 and sEng were higher and PlGF concentrations were
lower among PE cases (Table II). Comparing women who did not have PE but delivered
SGA infants and our referent group, PlGF levels were significantly lower, sEng levels were
slightly higher, but not as high as among PE cases, and sFlt-1 levels were not different
(Table II).
Since prior reports have suggested that angiogenic marker levels differ by severity of PE, we
subdivided PE cases by an indicator of severity (preterm (N=23, weighted frequency 41%)
and term (N=12; weighted frequency 59%). We found no statistically significant differences
in sFlt-1 levels between groups, but did observe PlGF levels tended to be lower in preterm
cases versus term (182.7 vs 259.8 pg/mL, p =0.10) and found higher sEng levels among
preterm as compared to term deliveries (2.11 vs 1.85 ng/mL, p = 0.04).
PE-like Patterns and PTD
Tables III and IV describe associations among the PE-like pattern and PTD grouped by
clinical circumstance and delivery timing. Low PlGF and High sEng were weakly associated
with PTD overall (Table III). Classified by clinical circumstance, Low PlGF (OR = 2.70;
95% CI 1.52–4.80) and High sEng (OR = 2.66; 95% CI 1.59–4.44) were significantly
associated with MI-PTD only. A comparison of means confirmed findings; only MI-PTD
showed significant alterations in PlGF (265.3 pg/mL vs. 385.1 pg/mL; p <0.0001) and sEng
(6.73 vs. 5.47 ng/mL; p <0.0001) vs. term deliveries. Grouped by delivery timing, Low
PlGF was associated with PTD <32 weeks (OR = 4.67; 95% CI 2.12–10.27, Table IV). High
sEng was associated with a two-fold increased odds of PTD <35 weeks.
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Removing PE and SGA cases from the analysis attenuated associations between Low PlGF
and High sEng among MI-PTD (Table III). This was mostly due to excluding PE cases.
Analyzed by delivery timing, sEng-PTD associations lost significance, most of the effect
attributable to PE. Despite removing PE and SGA cases, the association between low PlGF
and PTD <32 weeks persisted, OR = 3.35 (95% CI 1.40–8.03, Table IV). Findings were
unchanged if pregnancies complicated by other hypertensive disorders (chronic and
gestational hypertension) were excluded.
Low sFlt-1 and PTD
Table 5 presents associations between Low sFlt-1 and PTD. Initially, neither Low nor High
sFlt-1 was significantly associated with PTD. After removing PE and SGA cases from the
analysis, Low sFlt-1 was only associated with increased odds of MI-PTD (OR = 1.88; 95%
CI 0.89–3.96; Table V). The OR was similar and strengthened if only PE cases (OR = 2.19;
95% CI 1.08–4.45), all cases of hypertensive disorders (OR = 2.51 (95% CI 1.16–5.46) or if
PE/SGA and LGA cases were excluded. After the exclusion of PE and SGA cases, adjusted
mean sFlt-1 levels among MI-PTD tended to be lower than term pregnancies (1509 vs. 1819
pg/mL; p = 0.07), whereas for sPTD levels were non-significantly 45 pg/mL lower.
Discussion
In the POUCH Study, both PE-like and Low sFlt-1 patterns of angiogenic markers were
associated with elevated odds of MI-PTD among women who did not smoke during
pregnancy. First, we confirmed associations between PE and High s-Flt1, Low PlGF, and
High sEng. Then we observed that Low PlGF and High sEng were associated with PTD.
Most of the effect was attributable to PE, except low PlGF among PTD <32 weeks. Second,
Low sFlt-1 levels were associated with MI-PTD unexplained by PE or SGA. These patterns
may represent two different pathways, identifiable at midpregnancy, leading to PTD.
The PE-like (Low PlGF and High sEng) associations are largely due to preterm PE cases,
consistent with reports of more prominent angiogenic marker changes reported among
preterm PE vs. term or less severe PE[8,13]. When mean levels were compared in our study
(at an average of 22 gestational weeks’), sEng levels were clearly different between preterm
and term PE cases and PlGF levels were suggestive of differences, but not statistically-
significant ones. Studies point to a different disease course for preterm and term PE cases,
one that we were just beginning to pick up with our midpregnancy measures. In some
reports, differences in angiogenic marker levels between groups emerge around 17–23
weeks gestation, but that levels of PlGF do not discriminate between PE subtypes if
measured early in gestation [8,13], Differences in disease course reflected in the pattern of
angiogenic markers between preterm or term cases could influence clinical decision-making.
Because the POUCH Study participants received care from many clinicians within multiple
clinics/hospitals across 5 communities, it was not possible to define a set of clinical criteria
that lead to medically-indicated delivery among PE pregnancies. In our sample, 12 PE cases
were classified as SGA. Comparisons between frequency of SGA among preterm and term
PE cases as an indicator of severity are complicated by different meanings of SGA at
preterm and term gestations.[25] Additional information that would further help define
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severity of PE symptoms was unavailable, but 21 of the 23 PE and MI-PTD cases the main
indication for delivery was hypertension, perhaps suggestive of severe disease.
Consistent with the moderate strength of midpregnancy angiogenic marker-PE associations
reported in other studies [6,13] and PE-PTD cases driving most of the association between
the PE-like pattern of angiogenic markers and PTD, we observed odds ratios ~2–5. The
limited contribution of SGA may imply heterogeneity among cases, consistent with varied
reports of marker levels[8,9], or reflect fewer SGA cases compared with PE among MI-
PTD. The lack of a sFlt-1/PTD association is unsurprising given 1) inconsistent relations
between sFlt-1 levels measured before 20 weeks GA and PE[8,13,18] and 2) that sFlt-1
levels change later in pregnancy[8] relative to PlGF and sEng.
Reasons for the persistent association between Low PlGF and PTD <32 weeks are unclear.
There were too few observations to determine if factors like placental abruption or previous
PTD explain relations. The association may reflect a normal physiological shift as other
work suggests a PE-like biomarker pattern occurs in all pregnancies shortly before delivery
[8,17].
High levels of sFlt-1 and sEng are causally implicated in the development of hypertension
and proteinuria, characteristic signs and symptoms of PE[5,7]. Women with these
complications comprise a subset of MI-PTD that exhibits a PE-like marker pattern. Many
conditions associated with PE (e.g. hypoxia, immune imbalance, renin-angiotensin system
alterations) regulate angiogenic marker expression[4]. Alterations may be adaptive
responses to underlying pathology, but it is unclear if they directly contribute. Since some
women who develop PE do not exhibit High sFlt-1 and sEng[26,27], future work should
explore differences among preeclamptics who show changes in angiogenic markers and
those who do not to more fully describe the role of varying levels of angiogenic markers in
PE and PTD.
The relation between Low sFlt-1 and MI-PTD became apparent after our analysis was made
comparable to previous studies by removing PE/SGA or hypertensive cases. The exclusions
are reasonable since the PE-like pattern could mask subtle changes and it does not overlap
with the Low sFlt-1 pattern. While previous studies reported associations with sPTD or
sPTL[17,18], Low sFlt-1 was associated with a subset of MI-PTD in POUCH, most strongly
with cases uncomplicated by hypertension. Several factors could explain varied results
across studies. First, the populations studied differ (Chilean[17], Scottish[18], and US-
Michigan (POUCH)) and the spectrum of PTD cases may vary accordingly. Second, each
study defined sPTD or sPTL differently. Third, clinical practices vary across countries. MI-
PTD comprises a smaller proportion of PTD in Scotland and Latin America than in
POUCH[28,29]. If US clinical practice results in medical intervention for cases with Low
sFlt-1 levels, an association between Low sFlt-1 and MI-PTD would be observed. Perhaps
cases marked by Low sFlt-1 end in sPTD if no intervention occurs. Thus, variation in
clinical decision making or patient access/adherence to scheduled prenatal care visits might
explain inconsistent results across studies.
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After removing PE and SGA, 15 women in our sample had Low sFlt-1 and MI-PTD. Study
clinicians recorded indication for MI-PTD by reviewing hospital charts. Indications for the
above 15 women were: 4 maternal hypertension, 2 intrauterine growth restriction (IUGR), 1
placental abruption, 1 oligohydramnios, 3 complications in previous pregnancy, 2 placenta
previa and 2 non-reassuring fetal signs. The latter group had the lowest average sFlt-1
levels, but their removal only moderately attenuated the elevated risk of MI-PTD among the
Low sFlt-1 group. No single clinical circumstance linked low sFlt-1 and MI-PTD. One
underlying explanation might involve changes in placental oxygen levels, which partially
regulate sFlt-1 expression. Hypoxia increases expression[4], but placental hyperoxia, such as
that associated with fetal hypoxia in IUGR[30] may decrease sFlt-1 expression.
This study had several strengths. First, the use of a multiethnic, multi-community sample
demonstrated the strength of angiogenic marker-PTD associations in a diverse population of
nonsmokers with singleton pregnancies. Second, by not excluding women who had PE or
SGA at the design stage, we were able to selectively remove these women from the analysis
and determine their influence on findings in this population-based sample. Third, our
definition of PE was broader than some and may hint at the strength of angiogenic marker
associations within the spectrum of PE[4,6]. Finally, we were able to examine relations
among PTD subdivided by clinical circumstances and timing. Had MI-PTD been excluded
at the design stage, we would not have detected the Low sFlt-1/MI-PTD association or been
able to posit why our findings differ from others.
A limitation is the lack of repeated angiogenic marker measurements during pregnancy.
Recent work has demonstrated the utility of longitudinal measurements[8,17], showing
stronger associations between changes in biomarker concentrations and PE risk[31,32] and
SGA[33]. We did not adjust for multiple comparisons given our a-priori-stated hypothesis
that the PE-like pattern would be associated with PE and PTD. For comparisons with less
established angiogenic biomarker patterns, findings are noted as potentially indicative of a
relation and meriting further study.
This report confirms, extends and unifies previous work describing associations between
angiogenic markers and PTD, showing that angiogenic marker levels may reveal two
pathways leading to PTD. Additionally, the findings underscore the importance of
considering the overlap and interrelatedness of pregnancy conditions when studying
angiogenic markers. Finally, our results raise the possibility that variation in obstetric
practice might influence studies examining the utility of biomarkers for predicting and
understanding PTD.
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Flow diagram showing sample derivation, Pregnancy Outcomes and Community Health
Study
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Table V
Associations between High and Low sFlt-1 and PTD among non-smokers in POUCH (N=933)
Angiogenic sample, non-smokers
(N=933)
Angiogenic sample, non-smokers, excluding PE and
SGAd
(N=801)
Term sPTD MI PTD Term sPTD MI PTD
Angiogenic
Factora









High 204 40 0.81 (0.52–1.27) 19 1.14 (0.62–2.10) 174 38 0.83 (0.52–1.34) 6 0.80 (0.38–2.13)
Intermediate 352 83 33 303 76 16
Low 155 28 0.83 (0.50–1.37) 19 1.22 (0.67–2.29) 147 26 0.77 (0.45–1.29) 15 1.88 (0.89–3.96)
Total 711 151 71 624 130 37
a
Adjusted odds ratios (aOR) for each angiogenic factor (sFlt-1: soluble FMS-like tyrosine kinase-1) are adjusted for the following covariates: race,
parity, weight at enrollment, gestational age at enrollment, maternal age at enrollment
b
High: concentrations > 75th percentile of the distribution among term pregnancies having normal MSAFP. Low: concentration < 25th percentile
of the distribution among term pregnancies having normal MSAFP.
c
N represents number of observations for that category which had high sFlt-1, low PlGF, or high sEng levels
d
sPTD=spontaneous preterm delivery, MI-PTD=medically-indicated PTD, SGA=Small-for-Gestational Age [Ref 22]
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